ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

KPV

KPV

Also known as: KPV Tripeptide, Alpha-MSH Fragment 11-13

Overview

Key Facts

Primary Goal: A tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH)

A tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). Possesses potent anti-inflammatory properties without the melanogenic effects of the parent hormone. Half-Life ~30 minutes Typical Dose 200–500 mcg Frequency 1-2x daily Cycle Length 4-12 weeks

Dosing Information

Half-Life

~30 minutes

Typical Dose

200–500 mcg

Frequency

1-2x daily

Cycle Length

4-12 weeks

Administration Routes:

subcutaneousoraltopical

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2 weeks

Research Summary

Preclinical

Studied primarily in preclinical models of colitis, skin inflammation, and infection. Demonstrated ability to reduce intestinal inflammation in IBD mouse models comparable to standard treatments. Strong in vitro evidence for NF-kB pathway inhibition.

Frequently Asked Questions

Common questions about KPV

UK-Specific Information

Exclusive data points and guidance for UK residents using KPV

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With